Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tina Vilsbøll

Showing results (1-10 of 402) with videos related to

Pageof 41
Sort By:
Danish Medical Bulletin|July 13, 2005
On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitusTina Vilsbøll
Expert Opinion on Investigational Drugs|January 25, 2007
Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitusTina Vilsbøll
Expert Review of Endocrinology & Metabolism|February 13, 2019
Initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin for patients with Type 2 diabetes mellitusTina Vilsbøll
Nordic Journal of Psychiatry|May 7, 2016
Glucagon-like peptide-1 (GLP-1) analogues: A potential new treatment for alcohol use disorder?Anders Fink-Jensen, Tina Vilsbøll
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 10, 2008
Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitusTina Vilsbøll, Filip K Knop
Ugeskrift for Laeger|June 8, 2007
[GLP-1-based treatment of type 2 diabetes mellitus]Filip Krag Knop, Tina Vilsbøll
Med (New York, N.Y.)|August 9, 2025
SOUL searching in GLP-1 therapy: Oral semaglutide confirms cardioprotection in type 2 diabetesChristine Rode Schwarz, Tina Vilsbøll
Ugeskrift for Laeger|June 8, 2007
[Effect of incretin hormones GIP and GLP-1 for the pathogenesis of type 2 diabetes mellitus]Tina Vilsbøll, Filip Krag Knop
Nature Reviews. Endocrinology|May 6, 2017
Therapy: Liraglutide - preventing or postponing T2DM diagnosis?Tina Vilsbøll, Filip K Knop
Drugs|May 8, 2021
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 DiabetesAndreas Andersen, Filip Krag Knop, Tina Vilsbøll
Pageof 41

Showing results (1-10 of 402) with videos related to

Sort By:
Pageof 41
Danish Medical Bulletin|July 13, 2005
On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitusTina Vilsbøll
Expert Opinion on Investigational Drugs|January 25, 2007
Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitusTina Vilsbøll
Expert Review of Endocrinology & Metabolism|February 13, 2019
Initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin for patients with Type 2 diabetes mellitusTina Vilsbøll
Nordic Journal of Psychiatry|May 7, 2016
Glucagon-like peptide-1 (GLP-1) analogues: A potential new treatment for alcohol use disorder?Anders Fink-Jensen, Tina Vilsbøll
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 10, 2008
Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitusTina Vilsbøll, Filip K Knop
Ugeskrift for Laeger|June 8, 2007
[GLP-1-based treatment of type 2 diabetes mellitus]Filip Krag Knop, Tina Vilsbøll
Med (New York, N.Y.)|August 9, 2025
SOUL searching in GLP-1 therapy: Oral semaglutide confirms cardioprotection in type 2 diabetesChristine Rode Schwarz, Tina Vilsbøll
Ugeskrift for Laeger|June 8, 2007
[Effect of incretin hormones GIP and GLP-1 for the pathogenesis of type 2 diabetes mellitus]Tina Vilsbøll, Filip Krag Knop
Nature Reviews. Endocrinology|May 6, 2017
Therapy: Liraglutide - preventing or postponing T2DM diagnosis?Tina Vilsbøll, Filip K Knop
Drugs|May 8, 2021
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 DiabetesAndreas Andersen, Filip Krag Knop, Tina Vilsbøll
Pageof 41